Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Triple Negative Breast Cancer, Natural Killer Cells, BRCA Mutation
Interventions: LiquidBiopsy®, NK VueTM; Device
Lead sponsor: Cynvenio Biosystems; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 1
States / cities: Westlake Village, California

Conditions: Healthy
Interventions: Midazolam, PD-0332991; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Anxiety Depression
Interventions: Mindfulness-based art therapy, Art-only, Mindfulness-only; Other
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor, Multiple System Atrophy, Drug Induced Parkinson's Disease, Diffuse Lewy Body Disease, Myasthenia Gravis, Spinal Cord Injuries
Interventions: Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation, Peripheral Nerve Stimulation; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Adult Participants
Interventions: PF-07248144, Itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Eliglustat, Metoprolol; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Nausea, Vomiting
Interventions: ABH gel, placebo; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Nonimmune Fetal Hydrops, Nonimmune Hydrops in Neonate, Genetic Disorders
Interventions: Whole Exome Sequencing, Whole Genome Sequencing; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 16 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Malignant Hyperthermia
Interventions: Whole exome sequencing; Genetic
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Participants
Interventions: AZD5004, Itraconazole, EE/LNG; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: Danicamtiv; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Anterior Segment of Eye
Interventions: Lightfield Medical Vscan001 Automated Slit-lamp Camera; Device
Lead sponsor: Lightfield Medical; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Golden Valley, Minnesota

Conditions: Trichomonas Infections
Interventions: Not listed
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 4
States / cities: Flowood, Mississippi • Jackson, Mississippi

Conditions: Major Depressive Disorder
Interventions: Active Single-Pulse TMS, Sham Single-Pulse TMS, TARGET-optimized TMS, Non-optimized (Open-Loop) TMS, EEG Recording, Intracranial EEG (iEEG) Recording; Device · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Iowa City, California • Stanford, California

Conditions: Visual Acuity
Interventions: senofilcon A C3, Dailies Total 1® Multifocal Contact Lenses; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 6
States / cities: Jacksonville, Florida • Saint Augustine, Florida • Vestal, New York + 3 more

Conditions: Malignant Melanoma, Neoplasms
Interventions: Tizanidine, Vemurafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Pleasant Hill, California • Detroit, Michigan • Durham, North Carolina

Conditions: Healthy
Interventions: PF-06651600, Ethinyl estradiol (EE) and levonorgestrel(LN); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Coral Gables, Florida • Miami, Florida

Conditions: Diffuse Apneic Oxygenation
Interventions: Oxygen, Standard of care; Other
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Healthy Female Volunteers
Interventions: PF-06700841, Ethinyl estradiol (EE) and levonorgestrel (LN); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Coral Gables, Florida • Miami, Florida

Conditions: Healthy Adults
Interventions: PF-07220060, Itraconazole, Probenecid; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Female Volunteer
Interventions: D-0502; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Hypertension
Interventions: Metformin, CIN-107; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Drug Interaction
Interventions: Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate, Cohort 3 Probe Substrate Cocktail; Drug · Combination Product
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Alpha-Gal Syndrome, Allergy
Interventions: DBFC with 150g of Alpha-gal Knock Out (KO) pork, DBFC with 150g of Wild Type (WT) pork; Diagnostic Test
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 50 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Little Rock, Arkansas • Chapel Hill, North Carolina • Nashville, Tennessee + 1 more

Search by objective public record fields.

A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.

A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.

Mindfulness-Based Art Therapy and Generation Z

Biomarkers in Neural Disorders

A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)

Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults

Randomized Trial of the Effectiveness of Topical "ABH Gel" vs. Placebo in Cancer Patients With Nausea

Whole Exome Sequencing and Whole Genome Sequencing for Nonimmune Fetal/Neonatal Hydrops

Malignant Hyperthermia Registry and Genetic Testing

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants

A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants

Feasibility Study of a Novel Automated Slit Lamp Camera (Lightfield Medical Ophthalmic Camera Model Vscan001)

Trichomoniasis: Genotype and Phenotype Correlations in African American Women

Optimizing Brain Excitability in Depression

Evaluation of Investigational Daily Disposable Multifocal Contact Lenses Produced With Different Manufacturing Processes in Myopes

A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies

Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids

EmergeNcy Department Apneic Oxygenation Versus Usual Care During Rapid Sequence Intubation

Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids

A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060

Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects

Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG